Differences in Expression of Transcription Factor AP-1 in Human Promyelocytic HL-60 Cells During Differentiation Towards Macrophages Versus Granulocytes
Overview
Authors
Affiliations
Commitment of HL-60 cells to macrophage or granulocytic differentiation was achieved by incubation with 4 beta-phorbol 12-myristate 13-acetate (PMA) for 30-60 min or with dimethyl sulphoxide (DMSO) for 24 h respectively. The commitment stage towards PMA-induced macrophage differentiation was associated with increases in jun B and c-fos mRNA levels, as well as with an increase in the binding activity of transcription factor AP-1. Nevertheless, gel retardation analysis indicated that the AP-1 activity detected in untreated cells was drastically reduced during the commitment stage of DMSO-induced HL-60 differentiation towards granulocytes. When HL-60 cells were treated with sodium butyrate, which induced monocytic differentiation, a remarkable increase in AP-1 binding activity was detected. Treatment of HL-60 cells with 1 alpha,25-dihydroxyvitamin D3, another monocytic differentiation agent, induced a weak, but appreciable, increase in AP-1 activity. Furthermore, addition of sodium butyrate or 1 alpha,25-dihydroxyvitamin D3 to HL-60 cells induced the expression of c-fos, c-jun, jun B and jun D proto-oncogenes. In contrast, when HL-60 cells were treated with retinoic acid, a granulocytic differentiation inducer, no enhanced AP-1 binding activity was observed, and only a weak increase in jun D mRNA level was detected. These data indicate that formation of AP-1 is not required for the induction of HL-60 differentiation towards granulocytes, whereas induction of monocytic differentiation is correlated with an increase in AP-1 activity. The differential expression of AP-1 activity may be critical in the differentiation of HL-60 cells towards monocytic or granulocytic lineages.
Kotogany E, Balog J, Nagy L, Alfoldi R, Bertagnolo V, Brugnoli F Int J Mol Sci. 2020; 21(14).
PMID: 32698503 PMC: 7404197. DOI: 10.3390/ijms21145135.
Dakir E, Mollinedo F Oncotarget. 2019; 10(51):5313-5331.
PMID: 31523391 PMC: 6731105. DOI: 10.18632/oncotarget.27123.
Ganesh K, Das A, Dickerson R, Khanna S, Parinandi N, Gordillo G J Immunol. 2012; 189(5):2563-73.
PMID: 22844123 PMC: 3438225. DOI: 10.4049/jimmunol.1102762.
Schmeier S, MacPherson C, Essack M, Kaur M, Schaefer U, Suzuki H BMC Genomics. 2009; 10:595.
PMID: 20003307 PMC: 2797535. DOI: 10.1186/1471-2164-10-595.
Yang Z, Kondo T, Voorhorst C, Nabinger S, Ndong L, Yin F Mol Cell Biol. 2009; 29(16):4376-93.
PMID: 19528235 PMC: 2725726. DOI: 10.1128/MCB.01330-08.